51992
document
Naltrexone in autistic children : a double-blind and placebo-controlled study . A double-blind , placebo-controlled study was designed to assess critically the effects of naltrexone on behavioral symptoms and learning in autistic children , and its safety . This is a preliminary report on 18 children , ages 3.08 to 7.99 years , who completed this ongoing study . Subjects were randomly assigned to naltrexone or placebo and received daily doses over a period of 21 days . Naltrexone was superior to placebo according to blind Clinical Global Consensus Ratings ( unpublished scale ) . However , other behavioral rating measures did not confirm this result . There was only a suggestion that naltrexone reduced fidgety and hyperactive behavior and tended to alleviate overall symptomatology in older children . Naltrexone did not appear to affect discrimination learning . Results are preliminary and , owing to the small sample size , can be considered only suggestive until this study is completed or replication is obtained from independent research .
51993
Intervention_Pharmacological
Naltrexone
51994
Intervention_Pharmacological
naltrexone
51995
Intervention_Pharmacological
naltrexone
51996
Intervention_Control
placebo
51997
Intervention_Pharmacological
Naltrexone
51998
Intervention_Control
placebo
51999
Intervention_Pharmacological
naltrexone
52000
Intervention_Pharmacological
Naltrexone
52001
Outcome_Mental
behavioral symptoms
52002
Outcome_Mental
learning
52003
Outcome_Mental
Clinical Global Consensus Ratings
52004
Outcome_Mental
fidgety and hyperactive behavior
52005
Outcome_Mental
overall symptomatology
52006
Outcome_Mental
discrimination learning
52007
Participant_Condition
autistic
52008
Participant_Age
children
52009
Participant_Condition
:
52010
Participant_Condition
autistic
52011
Participant_Sample-size
18
52012
Participant_Age
children
52013
Participant_Age
3.08
52014
Participant_Age
7.99
52015
Participant_Age
older children